TORONTO – Hyivy Health Inc. has secured CA$1.1 million (US$888,000) in pre-seed funding to manufacture, test and obtain medical device approval for a women’s pelvic rehabilitation platform and to explore its use for relieving pelvic pain during clinical trials this summer.

Exoskeleton company Wandercraft SAS has landed $45 million in a series C round led by U.S. fund Quadrant Management. The company’s first commercial exoskeleton, Atalante, received CE marking in 2019 and has sold for around $176,000 a piece to European rehabilitation hospitals offering gait re-learning treatment.

Investors have backed Oxford University spin-off ONI Ltd. with $75 million to push commercialization of its nanoimaging technology. The startup’s flagship product Nanoimager is a desktop, super resolution microscope capable of visualizing, tracking, and imaging individual molecules in living cells with 20 nm resolution. The technology is already in use with biomedical companies to aid development of more efficient, targeted therapies.

Cancer therapy developer Immpact Bio USA Inc. has raised $111 million to further its "logic gate"-based CAR T-cell platform, the source of a CD19/CD20 bispecific in phase I testing for B-cell non-Hodgkin lymphoma patients whose disease has returned or who has stopped responding to treatment. New data from that study, showing complete remissions in seven of eight patients treated, accompanied the appointment of a new president and CEO for the company as well as a new board chair.